Novo Nordisk
NVO
#105
Rank
NZ$333.04 B
Marketcap
NZ$75.22
Share price
-0.76%
Change (1 day)
-39.21%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

EPS for Novo Nordisk (NVO)

EPS in 2026 (TTM): NZ$7.35

According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is NZ$7.48. In 2025 the company made an earnings per share (EPS) of NZ$6.18 an increase over its 2024 EPS that were of NZ$5.70.

EPS history for Novo Nordisk from 2016 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$7.3518.92%
2025NZ$6.188.48%
2024NZ$5.70
2016NZ$1.94

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.28-69.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$49.15 557.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$4.46-40.41%๐Ÿ‡ซ๐Ÿ‡ท France
Bristol-Myers Squibb
BMY
NZ$6.20-17.12%๐Ÿ‡บ๐Ÿ‡ธ USA